Nintedanib, a tyrosine kinase inhibitor targeting the PDGF, FGF, VEGF and M-CSF pathways, has shown comparable efficacy in IPF and SSc-ILD [5,16,21]. Here, CSF1 is linked to interstitial lung disease.